pmed.1003897.s004.docx (14.58 kB)
Instrument strength estimates for drug target instruments.
journal contribution
posted on 2022-02-03, 18:27 authored by James Yarmolinsky, Virginia Díez-Obrero, Tom G. Richardson, Marie Pigeyre, Jennifer Sjaarda, Guillaume Paré, Venexia M. Walker, Emma E. Vincent, Vanessa Y. Tan, Mireia Obón-Santacana, Demetrius Albanes, Jochen Hampe, Andrea Gsur, Heather Hampel, Rish K. Pai, Mark Jenkins, Steven Gallinger, Graham Casey, Wei Zheng, Christopher I. Amos, George Davey Smith, Richard M. Martin, Victor MorenoFootnote: Range represents r2 and F-stats across instruments applying a linkage disequilibrium threshold of <0.01 to <0.10.
(DOCX)
History
Usage metrics
Categories
Keywords
warranting comprehensive evaluationvariance weighted randomsystolic blood pressuresup >&# 8722naturally occurring variationmultivariable mendelian randomizationmodest statistical powermm hg reductionmendelian randomization assumptionsterm therapeutic inhibitiongenetically proxied inhibition450 controls ),support associations acrosspotential adverse effectsmendelian randomization analysis106 controls ).006 controls ).6 × 10term ace inhibitionace ), βwide association studiesreported conflicting findingsgenetically proxied longfinngen consortia data1 adrenergic receptorncc ), respectivelyantihypertensive drug targets4 common cancers0 × 10cancer risk analysesproxy inhibition93 ),finngen consortiumeffects modelsdrug targetscommon cancersanalysis includeace inhibitorsace 08 ).035 ).adrb1 ),gwas consortiaexamine associationsprostate ).xlink ">slc12a3 safety profilesreplication analysesprimary limitationsodds rationucleotide polymorphismslittle evidenceincreased riskincreased oddsfollowing cancerseuropean ancestryconverting enzymecolocalization analysesclinical trialsci 1ci 0chloride symportercancers examinedcancer riskadequate follow977 cases266 cases221 cases148 cases
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC